Cargando…

The value of EORTC risk tables in evaluating recurrent non–muscle–invasive bladder cancer in everyday practice

INTRODUCTION: Due to the risk of recurrence and progression, patients with non–muscle–invasive bladder cancer have to be under observation. The aim of this study is the evaluation of early recurrence at the first control cystoscopy, as a prognostic factor for recurrence and progression based on EORT...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walczak, Rafał, Bar, Krzysztof, Walczak, Janusz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Polish Urological Association 2013
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992449/ https://www.ncbi.nlm.nih.gov/pubmed/24757531 http://dx.doi.org/10.5173/ceju.2013.04.art6

Ejemplares similares

EORTC risk tables – their usefulness in the assessment of recurrence and progression risk in non–muscle–invasive bladder cancer in Polish patients
por: Borkowska, Edyta M., et al.
Publicado: (2013)

Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder
por: Xylinas, E, et al.
Publicado: (2013)

The Efficacy of the EORTC Scoring System and Risk Tables for the Prediction of Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer after Intravesical Bacillus Calmette-Guerin Instillation
por: Seo, Kyung Won, et al.
Publicado: (2010)

Do Standardised Prognostic Algorithms Reflect Local Practice? Application of EORTC Risk Tables for Non-Muscle Invasive (pTa/pT1) Bladder Cancer Recurrence and Progression in a Local Cohort
por: Pillai, Rajiv, et al.
Publicado: (2011)

Predicting Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer in Korean Patients: A Comparison of the EORTC and CUETO Models
por: Choi, Se Young, et al.
Publicado: (2014)

EORTC risk tables are more suitable for Chinese patients with nonmuscle-invasive bladder cancer than AUA risk stratification
por: Wang, Hui, et al.
Publicado: (2018)

Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin
por: Alkhateeb, Sultan S., et al.
Publicado: (2011)

External validation of EORTC risk scores to predict recurrence after transurethral resection of brazilian patients with non-muscle invasive bladder cancer stages Ta and T1
por: Almeida, Gilberto L., et al.
Publicado: (2016)

Utility of a Molecular Signature for Predicting Recurrence and Progression in Non-Muscle-Invasive Bladder Cancer Patients: Comparison with the EORTC, CUETO and 2021 EAU Risk Groups
por: Piao, Xuan-Mei, et al.
Publicado: (2022)

Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer
por: Ripping, Theodora M., et al.
Publicado: (2021)

Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non–muscle‐invasive bladder cancer (NMIBC): A cohort analysis
por: Jobczyk, Mateusz, et al.
Publicado: (2020)

Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non–muscle-invasive bladder cancer and with low and intermediate EORTC-risk score
por: Simon, Marie, et al.
Publicado: (2019)

A Comparison of the Progression and Recurrence Risk Index in Non-Muscle-Invasive Bladder Tumors Detected by Narrow-Band Imaging Versus White Light Cystoscopy, Based on the EORTC Scoring System
por: Shadpour, Pejman, et al.
Publicado: (2016)

Validation and Reliability Testing of the EORTC QLQ-NMIBC24 Questionnaire Module to Assess Patient-reported Outcomes in Non–Muscle-invasive Bladder Cancer
por: Blazeby, Jane M., et al.
Publicado: (2014)

Prognostic value of prostate volume in non-muscle invasive bladder cancer
por: Ham, Won Sik, et al.
Publicado: (2021)

Urinary Metabolic Signatures Detect Recurrences in Non-Muscle Invasive Bladder Cancer
por: Loras, Alba, et al.
Publicado: (2019)

Somatic Mutation of the Non-Muscle-Invasive Bladder Cancer Associated with Early Recurrence
por: Yu, Seong Hyeon, et al.
Publicado: (2023)

Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence
por: Zhang, Jianglei, et al.
Publicado: (2021)

Development and Validation of the Korean Version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients with Non-muscle Invasive Bladder Cancer: EORTC QLQ-NMIBC24
por: Park, Jinsung, et al.
Publicado: (2018)

Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer
por: Quhal, Fahad, et al.
Publicado: (2021)

Validation and reliability of the Dutch version of the EORTC QLQ-BLM30 module for assessing the health-related quality of life of patients with muscle invasive bladder cancer
por: Ripping, T. M., et al.
Publicado: (2022)

The association of BMI with risk of recurrence and progression in patients with non-muscle-invasive bladder cancer
por: Vrieling, Alina
Publicado: (2018)

Predicting Recurrence of Non-Muscle-Invasive Bladder Cancer: Current Techniques and Future Trends
por: Shalata, Aya T., et al.
Publicado: (2022)

Limited Value of Bladder Wash Cytology During Follow-Up of Patients With Non-muscle Invasive Bladder Cancer
por: Bieri, Uwe, et al.
Publicado: (2023)

Predictors of Outcome of Non–Muscle-Invasive and Muscle-Invasive Bladder Cancer
por: Youssef, Ramy F., et al.
Publicado: (2011)

Prognostic Value of Sex-Hormone Receptor Expression in Non-Muscle-Invasive Bladder Cancer
por: Nam, Jong Kil, et al.
Publicado: (2014)

The value of molecular markers in classification and prediction of progression in non-muscle-invasive bladder cancer
por: Pan, Chin-Chen
Publicado: (2018)

Prognostic Value of BUB1 for Predicting Non-Muscle-Invasive Bladder Cancer Progression
por: Piao, Xuan-Mei, et al.
Publicado: (2021)

Prognostic value of the systemic immune-inflammation index in non-muscle invasive bladder cancer
por: Katayama, Satoshi, et al.
Publicado: (2021)

Collagen stiffness promoted non-muscle-invasive bladder cancer progression to muscle-invasive bladder cancer
por: Zhu, Huier, et al.
Publicado: (2019)

Prostatic urethra recurrence after transurethral resection of bladder tumor (TURBT) for non‐muscle‐invasive bladder cancer (NMIBC)
por: Bilim, Vladimir, et al.
Publicado: (2022)

Xpert Bladder Cancer Monitor for the Early Detection of Non-Muscle Invasive Bladder Cancer Recurrences: Could Cystoscopy Be Substituted?
por: Lozano, Fernando, et al.
Publicado: (2023)

TERT C228T mutation in non‐malignant bladder urothelium is associated with intravesical recurrence for patients with non‐muscle invasive bladder cancer
por: Hayashi, Yujiro, et al.
Publicado: (2020)

GSTM1 Tissue Genotype as a Recurrence Predictor in Non-muscle Invasive Bladder Cancer
por: Ha, Yun-Sok, et al.
Publicado: (2011)

GSTT1 as a Prognosticator for Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer
por: Ha, Yun-Sok, et al.
Publicado: (2010)

Lower cyclooxygenase-2 expression is associated with recurrence of solitary non-muscle invasive bladder carcinoma
por: Tadin, Tomislav, et al.
Publicado: (2012)

The association between the recurrence of solitary non-muscle invasive bladder cancer and tumor infiltrating lymphocytes
por: Krpina, Kristian, et al.
Publicado: (2012)

Early isolated bone metastases without local recurrence in non-muscle invasive bladder cancer
por: Hong, Jeong Hee
Publicado: (2015)

Urinary biomarker for the detection of recurrence following non-muscle invasive bladder cancer: are we there yet?
por: Tan, Wei Shen, et al.
Publicado: (2018)

Impact of Occupational Exposures and Genetic Polymorphisms on Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer
por: Carta, Angela, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lm552i8vo8ssfaj8360mj2pals